US EditionDepression spray to be cheaper for Aussie patients
- Spravato, a nasal spray containing esketamine for difficult-to-treat depression, joins Australia's Pharmaceutical Benefits Scheme from May 1, 2025.
- This addition follows patients like Samuel Hockey experiencing limited success with previous standard treatment options.
- Administering the medication requires supervised clinical sessions due to potential disorienting effects on patients.
- Costs drop significantly per dose, marking the first new government-funded depression medication added in three decades.
- While the PBS listing improves drug affordability, researchers highlight that clinic fees still present a barrier to broader patient access.
Insights by Ground AI
Does this summary seem wrong?
18 Articles
18 Articles
All
Left
8
Center
Right
4
Depression treatment funding breaks 30-year drought
The federal government is set to fund a new type of medicine for major depression. (Lukas Coch/AAP PHOTOS) By Samantha Lock A mind-altering medication chemically akin to ketamine will be made cheaper to improve the lives of Australians suffering from treatment-resistant depression – the first new government-backed initiative to treat the chronic mental illness in decades. The drug – which comes in the form of a nasal spray – is a chemical cousin…
·Canberra, Australia
Read Full ArticleCoverage Details
Total News Sources18
Leaning Left8Leaning Right4Center0Last UpdatedBias Distribution67% Left
Bias Distribution
- 67% of the sources lean Left
67% Left
L 67%
R 33%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
